Cafepharma Today

March 27 2023 - Novartis' Kisqali cuts recurrence risk in early-stage breast cancer
Novartis' Kisqali cuts recurrence risk in early-stage breast cancer
Novo's high-dose Rybelsus win tees up regulatory filings
BioNTech's COVID-19 vaccine revenue forecasts lower than expected
BrainStorm secures FDA adcomm for ALS therapy NurOwn
*please scroll down for all the latest news*

Current News

submit a press release

Click here to stay updated on CP happenings
Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Fierce Pharma
Tuesday, March 21, 2023 - 9:58pm
tags:
Eisai, Leqembi, FDA, CMS, Alzheimer's disease
FTC says patent battle over Parkinson's drug could have 'significant implications' for patients
Endpoints
Tuesday, March 21, 2023 - 9:56pm
tags:
FTC, Parkinson's Disease, Apokyn, Supernus Pharmaceuticals, Sage Chemical, patents
Gilead’s Yescarta extends survival in lymphoma study
BioPharma Dive
Tuesday, March 21, 2023 - 9:53pm
tags:
Gilead Sciences, Yescarta, CAR-T, lymphoma, large B-cell lymphoma
Biopharma industry lobbies for tax breaks related to US-based manufacturing
Fierce Pharma
Tuesday, March 21, 2023 - 9:50pm
tags:
taxes, drug manufacturing
New Yale study evaluates PAXLOVID's use in Long COVID recovery
Drugs.com
Tuesday, March 21, 2023 - 9:49pm
tags:
Pfizer, Paxlovid, COVI-19, Long COVID, clinical trials
FDA's Peter Marks backs accelerated approval for gene therapies
BioSpace
Tuesday, March 21, 2023 - 11:36am
tags:
FDA, CDER, Peter Marks, gene therapy, accelerated approval
Altimmune's obesity drug throws up safety concerns, shares plunge
Yahoo/Reuters
Tuesday, March 21, 2023 - 10:10am
tags:
Altimmune, obesity, clinical trials
Return of the megaround: Is biotech back from the brink?
Fierce Biotech
Tuesday, March 21, 2023 - 10:08am
tags:
Rapport Therapeutics, Noema Pharma, Bicara Therapeutics, funding, venture capital
Incyte touts mid-stage data for new JAK inhibitor but stops short of selecting PhIII dose
Endpoints
Tuesday, March 21, 2023 - 10:06am
tags:
AAD, Incyte, JAK inhibitors, povorcitinib, vitiligo
BioNTech signs deal to co-develop OncoC4's cancer drug
Reuters
Tuesday, March 21, 2023 - 10:05am
tags:
BioNTech, OncoC4, cancer, oncology, drug development, ONC-392
Marketers expected to scrutinize partner contracts post-SVB collapse
Medical Marketing and Media
Tuesday, March 21, 2023 - 10:03am
tags:
SVB, banking, pharma marketing
Evofem makes top-to-bottom cuts to save cash, slashing CEO pay by 40% and eliminating positions
Fierce Biotech
Tuesday, March 21, 2023 - 10:01am
tags:
Evofem Biosciences, layoffs, contraceptives, Women's Health
Selecta, Sobi rout gout in pair of phase 3 trials that could challenge Horizon
Fierce Biotech
Tuesday, March 21, 2023 - 10:00am
tags:
Sobi, Selecta Biosciences, gout, SEL-212, Horizon Therapeutics, Krystexxa
FDA grants fast track designation to Arrowhead Pharmaceuticals’ ARO-APOC3 to reduce triglycerides
Pharmaceutical Business Review
Tuesday, March 21, 2023 - 9:57am
tags:
Arrowhead Pharmaceuticals, ARO-APOC3, triglycerides, familial chylomicronemia syndrome, fast track, FDA
The Rise, Fall and Future of Novavax
BioSpace
Tuesday, March 21, 2023 - 9:55am
tags:
Novavax, vaccines, COVID-19
AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
EP Vantage
Tuesday, March 21, 2023 - 9:54am
tags:
AAD, hidradenitis suppurativa, AbbVie, Humira, UCB Pharma, Bimzelx, Acelyrin, izokibep
FDA’s top cybersecurity officials discuss heightened threats, technology modernization
RAPS.org
Tuesday, March 21, 2023 - 9:53am
tags:
FDA, cybersecurity, modernization
Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing
NASDAQ
Monday, March 20, 2023 - 4:47pm
tags:
Novartis, SMA, Zolgensma, gene therapy
A sign of what's coming? Presidential hopeful DeSantis targets PBMs and pharma transparency
Endpoints
Monday, March 20, 2023 - 4:44pm
tags:
PBMs, transparency, Ron DeSantis, drug pricing
Illumina, facing Icahn challenge, ‘moving quickly’ on resolution for Grail
BioPharma Dive
Monday, March 20, 2023 - 4:42pm
tags:
Illumina, Grail, M&A, Medtech, diagnostics, Carl Icahn

Pages

Latest CP Wire Articles

PharmaBlock Opens New R&D Facility in Pennsylvania ——Expanding Capacity to Deliver GMP Projects
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Klick Health launches new healthcare venture studio
Medtech earnings reports: insights from major players' Q4 results
Key compliance issues for medtech firms transitioning to data-enabled solutions
Following FDA COVID vaccine advisory panel vote, Novavax is prepared to provide a revised vaccine
First-of-its-kind Whole Lung Simulator is Helping Michigan Researchers Predict New Treatments and Vaccines for TB – A Reemerging Global Health Threat
Novartis signs agreement with UN-backed Medicines Patent Pool to license generics of its CML drug
Korean firm LG Chem buying AVEO Oncology for $566M

Latest Pharmagather Articles

Behind the GoodRx-Express Scripts Partnership: How PBMs Profit from Discount Cards in Pharmacy Benefits (rerun)
Drug Channels
Winning the Race for Patient Access: Identifying Copay Accumulator Impact
Drug Channels
Gene Drives Are Coming
In the Pipeline
Organizing Our Thoughts About Cells - Finally
In the Pipeline
Drug Channels News Roundup, March 2023: My $0.02 on Insulin Price Cuts, AbbVie vs. AFPs, Optum Expands, ASAP340B, and Hooray for Pharmacists
Drug Channels
The Right Assay With the Right Cells
In the Pipeline
Informa Connect’s Annual Life Sciences Commercial Contracts & Chargebacks Congress
Drug Channels
Peptide-Encoded Screening Libraries
In the Pipeline
It's Not All Bad News: Data Shows There's a Collaborative Future for 340B
Drug Channels

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.

Do Not Allow Advertisers to Use My Personal information